Buy Figitumumab ELISA Kit

Catalog No.

KDC29903

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human CD221 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Figitumumab in the sample competitively binds to the pre-coated protein with biotin-labeled Figitumumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Figitumumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Figitumumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

62.5 - 4,000 ng/mL

Sensitivity

10.24 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	2171.2	444.5	113.9	2165.2	487.5	132.8
Standard deviation	144.2	39.5	16.4	218.1	41.0	18.7
CV (%)	6.6	8.9	14.4	10.1	8.4	14.1

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

CP-751871, CAS: 943453-46-1

Background

Figitumumab is a fully humanized IgG2 mAb against IGF-1R. Its recommended dose is 20 mg/kg repeated weekly. In phase I trials treatment-related toxicities were generally mild. The most common adverse events reported were hyperglycemia, anorexia, nausea, elevation of liver function tests, diarrhea, hyperuracemia and fatigue. Figitumumab had shown significant activity against non-small-cell lung cancer (NSCLC) and it was planned to be evaluated in combination with chemotherapy in a randomized phase III trial in patients with metastatic NSCLC. However, the study was early discontinued on December 2009 because an independent monitoring committee concluded that the combination of figitumumab plus chemotherapy would be unlikely to meet the primary endpoint of improving overall survival compared to chemotherapy alone. Additionally, there were also some concerns that hyperglycemia could be a potential contributor of increased patients’ morbidity. In regard to breast cancer, figitumumab was planned to be tested in phase I trials as neo-adjuvant treatment, but the trial was withdrawn prior initiation, although there are preclinical data showing a additive and/or synergistic effect of figitumumab with chemotherapy in basal breast cancer subtype.

Experiment Example

CALCULATION OF RESULTS
Average the duplicate readings for each standard and sample. Construct a standard curve by plotting the mean absorbance for each standard on the Y-axis against the concentration on the X-axis and draw a best fit curve through the points on the graph. Do not include the blank in the standard curve. The data may be linearized by plotting the log of the Figitumumab concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors., PMID:38136399

The Immunotherapy Landscape in Adrenocortical Cancer., PMID:34071333

A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer., PMID:33725344

Osteosarcoma Pathogenesis Leads the Way to New Target Treatments., PMID:33467481

Advances in antibody therapeutics targeting small-cell lung cancer., PMID:29790694

Emerging immune targets for the treatment of multiple myeloma., PMID:29421983

Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation., PMID:29137261

Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy., PMID:28427155

Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease., PMID:28236033

IGFBP, a novel target of lung cancer?, PMID:28104361

Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors., PMID:27831000

[Clinical trials and licensing of monoclonal antibodies and biological medicines for cancer treatment in Brazil]., PMID:27754528

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors., PMID:27733479

IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias., PMID:27532210

Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC., PMID:27488947

Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation., PMID:27437872

Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies., PMID:27377311

Insulin-like Growth Factor Receptor Inhibition as Maintenance Therapy for Metastatic Ewing Sarcoma., PMID:27322713

Emerging antibodies for the treatment of multiple myeloma., PMID:27195659

Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway., PMID:26801096

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade., PMID:26429980

Minireview: Were the IGF Signaling Inhibitors All Bad?, PMID:26366975

Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer., PMID:26287334

In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib., PMID:26195122

The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer., PMID:25806342

The failure of figitumumab: the danger of taking shortcuts in drug development., PMID:25524479

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer., PMID:25395283

Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma., PMID:25358597

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer., PMID:24888810

Targeting receptor tyrosine kinases in gastric cancer., PMID:24782606

The effects of insulin-like growth factor 1 and growth hormone on human meibomian gland epithelial cells., PMID:24743973

Emerging therapeutic targets for synovial sarcoma., PMID:24661286

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer., PMID:24536060

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial., PMID:24488322

Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug., PMID:24391834

Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871)., PMID:24107449

The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy., PMID:24033707

Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor., PMID:23826179

Pharmacokinetics and pharmacodynamics of figitumumab, a monoclonal antibody targeting the insulin-like growth factor 1 receptor, in healthy participants., PMID:23400740

Retraction. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab., PMID:23211971

β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma., PMID:23188799

Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers., PMID:23051797

[Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting]., PMID:22883466

Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma., PMID:22798295

Insulin-like growth factor receptor inhibitors: baby or the bathwater?, PMID:22761272

A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer., PMID:22553344

Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody., PMID:22438913

Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls., PMID:22423264

Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02)., PMID:22234739

Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft., PMID:22184402

Document Download

Figitumumab ELISA Kit.pdf

Figitumumab ELISA Kit